CGRP & Migraine Research
Explore migraine research on CGRP biology, CGRP-targeted treatments, efficacy, safety and emerging therapeutics.
-
Safety and Efficacy of Atogepant for Migraine Prevention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Authors: Akram Nizamani S, Memon R, Iguh C, Ali R, Omomhenle OD Systematic review / meta-analysis
Migraine is a common neurological disorder that can severely affect daily life. Atogepant is a new oral medication designed to prevent migraines. This study reviewed six high-quality trials involving 3,453 patients…
-
Fremanezumab for the preventive treatment of migraine in Chinese adults: A Phase 3, randomized controlled trial with an open-label extension.
Authors: Yu S, Su H, Wang H, Zhang M, Barash S Clinical trial
Fremanezumab is a treatment approved for migraine prevention in many countries. This study focused on its effects in Chinese adults with migraines. Researchers conducted a Phase 3 trial with three groups. One group…
-
Ultrasound assessment of cerebrovascular risk via breath-holding index in migraine patients treated with anti-CGRP monoclonal antibodies: a pilot study.
Authors: Barbella G, Antenucci P, Govoni V, Casetta I, Paciaroni M Observational study
Migraine is a highly disabling condition affecting many people worldwide. New treatments using monoclonal antibodies target a specific pathway related to migraines. However, their effects on blood flow in the brain…
-
[Treatment persistence and adherence with botulinum toxin type A and anti-calcitonin gene-related peptide monoclonal antibodies in migraine. (A retrospective cohort study from a specialized headache center)].
Authors: Naprienko MV, Zharashueva LA Observational study
This study looked at how well migraine patients stick to treatments. It compared two options: botulinum toxin type A (BTA) and monoclonal antibodies targeting calcitonin gene-related peptide (anti-CGRP mAb)…
-
Twelve-months prospective real-world assessment of effectiveness and safety of eptinezumab in migraine patients difficult-to-treat and naïve to CGRP monoclonal antibodies: results of the French FHU INOVPAIN registry.
Authors: Ferrao-Malheiro S, Fabre R, Jiacomini T, Lanteri-Minet M Observational study
This study looked at how effective and safe a drug called eptinezumab is for migraine patients in real life. The research involved 302 patients from a French hospital registry. Most of the patients were women, and…
-
Association of Serum hs-CRP and TNF-α With Therapeutic Response to Erenumab for Migraine Prevention: A Registry for Migraine (REFORM) Study.
Authors: Karlsson WK, Christensen RH, Al-Khazali HM, Olsen DA, Madsen JS Observational study
This study explored the role of inflammatory markers in predicting migraine treatment success. Researchers focused on two markers: high-sensitivity C-reactive protein and tumor necrosis factor-alpha. They studied…
-
Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial.
Authors: Reuter U, Dycke AV, Versijpt J, Holle-Lee D, Farkas MK Clinical trial
This research compares atogepant and topiramate for preventing migraines. Atogepant, a new oral treatment, is a CGRP receptor antagonist. Topiramate is an older, widely used preventive migraine treatment. However…
-
Calcitonin Gene-Related Peptide Monoclonal Antibody Utilization and Treatment Gaps in People with Migraine in Japan: Results from the OVERCOME (Japan) 2nd Study.
Authors: Hanaoka Y, Takizawa T, Ishii R, Danno D, Hamakawa M Observational study
Calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) effectively prevent migraines. However, their use in Japan remains low. The OVERCOME (Japan) 2nd study analyzed CGRP mAb utilization patterns and…
-
Cochlear Functional Changes and CGRP Modulation in a Chronic Nitroglycerin Migraine-Like Rat Model.
Authors: Koçdor P, Shomalizadeh N, Salman FA, Demirhan F, Erbaba B Laboratory / animal study
Auditory and vestibular symptoms in migraine and inner ear conditions overlap significantly. However, the mechanisms linking migraine biology to inner ear dysfunction are still unclear. This study explored the role…
-
PRT-064040: A nasal spray of novel, potent, and selective calcitonin gene-related peptide receptor antagonist for migraine.
Authors: Du S, Yang H, Yue J, Wang H, Kou R Laboratory / animal study
Calcitonin gene-related peptide, or CGRP, is linked to migraine and other conditions. Researchers developed a new nasal spray called PRT-064040. This drug acts as a CGRP receptor antagonist. It aims to meet the…
-
A delayed endothelial-glial mechanism for CGRP-induced migraine.
Authors: Lennerz JK, Messlinger K Review
CGRP plays a crucial role in migraine and trigeminovascular signaling. However, how CGRP causes delayed migraine-like pain after infusion is unclear. Although evidence supports CGRP’s role, the exact mechanisms…
-
Chronic migraine management with onabotulinumtoxinA and anti-CGRP/R monoclonal antibodies in an Italian real-world setting: update on therapeutic appropriateness and an emerging role of pharmacy.
Authors: Scuteri D, Naturale MD, Pagliaro M, Brescia A, De Francesco AE Guideline / consensus
Migraine is a challenging neurovascular disorder that can progress to chronic forms. This progression may result in medication-overuse headache, leading to higher healthcare costs. The need for preventive treatments…
-
Real-world outcomes of zavegepant use in a tertiary care setting using the Migraine Treatment Optimization Questionnaire-5.
Authors: Dunn E, Ong B, Kaur H, Popov R, Sonneborn C Observational study
The introduction of calcitonin gene-related peptide antagonists has changed migraine treatment. Zavegepant is a third-generation intranasal gepant for acute migraine relief. Although clinical trials show its…
-
Patient Experience with 10 mg Intranasally Administered Zavegepant as an Acute Treatment of Migraine Attacks: Qualitative Research Findings.
Authors: Rosen N, Moran H, Coulter J, Kissling A, You W Observational study
Migraine is a significant burden on individuals and healthcare systems alike. This study investigates patient experiences with zavegepant 10 mg intranasal for acute migraine treatment. Adults with self-reported…
-
Early and clinically meaningful functional improvement following CGRP monoclonal antibodies in adolescents with migraine: A real-world retrospective study.
Authors: Kamogawa M, Higurashi M, Oshima A, Higurashi N, Ikegaya N Observational study
CGRP monoclonal antibodies (mAb) could help adolescents with migraines. This study focused on adolescents aged 15-17 years who received CGRP mAb therapy for migraine. It evaluated early functional outcomes in daily…
-
Three-Year Interim Results from a Post-Marketing Surveillance Study of Patients with Migraine Treated with Fremanezumab in South Korea.
Authors: Seo D, Kim M, Lee MJ, Chu MK, Cho SJ Observational study
Fremanezumab is being evaluated for its safety and effectiveness in South Korea. This study focuses on adults with migraines using fremanezumab for the first time. It is a 6-year, non-interventional study across 60…
-
Rimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project).
Authors: Gago-Veiga AB, Lopez-Rodriguez AB, Sanchez Jimenez M, Iglesias Rubio A, Montes N Observational study
Rimegepant is a CGRP receptor antagonist for treating episodic migraines. This study examined rimegepant's effectiveness in patients with previous treatment failures. It was conducted across nine headache units in…
-
Trigeminovascular calcitonin gene-related peptide release and peripheral vascular responses in a mouse model of accelerated aging: Implications for migraine.
Authors: Al-Hassany L, Rubio-Beltrán E, Labastida-Ramirez A, Garrelds IM, Danser AHJ Laboratory / animal study
Understanding age-related changes in migraine is crucial as life expectancy increases. Both aging and migraine are significant cardiovascular risk factors. Researchers studied how calcitonin gene-related peptide…
-
Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension study.
Authors: Bond DS, Smith JH, Sinclair A, Goadsby PJ, Ailani J Clinical trial
This study examined weight loss with atogepant 60 mg daily for migraine treatment. Participants had chronic or episodic migraine and had previously failed several medications. Obesity increases migraine risk…
-
CGRP-Targeted Therapy in Vestibular Migraine-How Strong Is the Evidence?
Authors: Tarnutzer AA, Castro Abarca P, Kaski D Clinical trial
CGRP-targeted therapies have shown promise in reducing migraine symptoms for many patients. However, evidence for their effectiveness in vestibular migraine is limited and preliminary. Current literature on…